Humanigen, Inc.
HGENDrugs in Pipeline
9
Phase 3 Programs
5
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 0 past
No catalysts found.
Belimumab
Systemic Lupus Erythematosus
Azathioprine
Vasculitis
Belimumab 10 mg/kg plus standard therapy
Lupus Nephritis
Belimumab 1 mg/kg
Systemic Lupus Erythematosus
Belimumab 200 mg SC
Systemic Lupus Erythematosus
Mapatumumab
Carcinoma, Hepatocellular
Anti-GM-CSF Monoclonal Antibody 400mg
Moderate-to-Severe Asthma
KB001-A
Cystic Fibrosis
KB001
Pseudomonas Aeruginosa
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Belimumab | Phase 3 | Systemic Lupus Erythematosus | - | - |
Azathioprine | Phase 3 | Vasculitis | - | - |
Belimumab 10 mg/kg plus standard therapy | Phase 3 | Lupus Nephritis | - | - |
Belimumab 1 mg/kg | Phase 3 | Systemic Lupus Erythematosus | - | - |
Belimumab 200 mg SC | Phase 3 | Systemic Lupus Erythematosus | - | - |
Mapatumumab | Phase 2 | Carcinoma, Hepatocellular | - | - |
Anti-GM-CSF Monoclonal Antibody 400mg | Phase 2 | Moderate-to-Severe Asthma | - | - |
KB001-A | Phase 2 | Cystic Fibrosis | - | - |
KB001 | Phase 2 | Pseudomonas Aeruginosa | - | - |
Frequently asked questions
What is in Humanigen, Inc.'s drug pipeline?→
CatalystAlert tracks 9 drug candidates in Humanigen, Inc.'s (HGEN) pipeline across Phase 3, Phase 2. Its lead program is Belimumab (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Humanigen, Inc.'s next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for Humanigen, Inc. (HGEN) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track HGEN biotech catalysts?→
Add HGEN to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Humanigen, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.